RXRA · Western blot design guide

RXRA Western Blot Planning Guide

Plan a RXRA Western blot around the catalog-observed 50.8 kDa band, image-backed A01299-1 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for RXRA: expected band 50.8 kDa observed, antibody A01299-1, and PMC-cited SDS-PAGE protocol steps
RXRA Western blot protocol sheet — expected band 50.8 kDa observed, antibody A01299-1, controls and PMC citations. Open the full RXRA WB guide →

RXRA Western Blot Experimental Design Guide

Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 50.8 kDa observed
Observed band 50.8 kDa observed
Gel 12-15%
Positive control ⓘ Adrenal gland
Negative control ⓘ Use knockout/knockdown or orthogonal negative
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 50.8 kDa
ⓘ Localization Nucleus / Cytoplasm
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Mouse / Rat
Section 1

Real Curated RXRA Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateAdrenal gland
Gel %12-15%
Load20-30 µg total protein per lane
TransferSemi-dry, standard transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryA01299-1 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected RXRA Western Blot Band Size?

Use the product-observed 50.8 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
50.8 kDaMatches the authoritative product WB observation.
50.8 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected RXRA appearancePlan around 50.8 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band50.8 kDa; use this as the primary experimental expectation.
Calculated mass50.8 kDa from UniProt P19793; retain as context.
Gel selection12-15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with A01299-1.
Why is my band missing or off?
SituationLikely causeNext action
50.8 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for RXRA Western blot

🧪Use Adrenal gland as the first positive-control candidate and retain an orthogonal negative control.
Positive control: Adrenal gland (High)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for RXRA

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Adrenal gland Reported tissue cells High Protein (HPA) HPA →
Breast Reported tissue cells High Protein (HPA) HPA →
Appendix Reported tissue cells High Protein (HPA) HPA →
Bone marrow Reported tissue cells High Protein (HPA) HPA →
Cerebral cortex Reported tissue cells Medium Protein (HPA) HPA →
Duodenum Reported tissue cells Medium Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Section 3

Advanced RXRA Western Blot Tips

Deeper troubleshooting and optimisation questions for RXRA, answered from its protein features.

Which band should guide the blot?
Use 50.8 kDa, the observation attached to the authoritative A01299-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 50.8 kDa expectation.
Which positive control should I start with?
Start with Adrenal gland, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use a target knockdown/knockout control when no HPA Not detected tissue is available.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for RXRA Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A01299-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

RXRA Western Blot Reagents

Human/Mouse/Rat-reactive RXRA Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for RXRA using A01299-1; observed band 50.8 kDa
Anti-Retinoid X Receptor alpha/RXRA Antibody Picoband®
Cat # A01299-1
Real WB data Western blot validation image for RXRA using A01299-2; observed band 50.8 kDa
Anti-RXRA Antibody Picoband®
Cat # A01299-2
Real WB data Western blot validation image for RXRA using M01299; observed band 50.8 kDa
Anti-Retinoid X Receptor alpha/RXRA Antibody Picoband® (monoclonal, 5E7)
Cat # M01299

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt P19793
  2. Human Protein Atlas — RXRA
  3. A01299-1 product record
  4. PMC12333201 — CCT196969 inhibits TNBC by targeting the HDAC5/RXRA/ASNS axis to down-regulate asparagine synthesis (Journal of experimental & clinical cancer research : CR, 2025)
  5. PMC8804561 — RXRA DT448/9PP generates a dominant active variant capable of inducing maturation in acute myeloid leukemia cells (Haematologica, 2022)